ATE526020T1 - Gesteigertes kognitives training - Google Patents

Gesteigertes kognitives training

Info

Publication number
ATE526020T1
ATE526020T1 AT01963877T AT01963877T ATE526020T1 AT E526020 T1 ATE526020 T1 AT E526020T1 AT 01963877 T AT01963877 T AT 01963877T AT 01963877 T AT01963877 T AT 01963877T AT E526020 T1 ATE526020 T1 AT E526020T1
Authority
AT
Austria
Prior art keywords
methods
cognitive training
cognitive
neuronal activity
increased cognitive
Prior art date
Application number
AT01963877T
Other languages
English (en)
Inventor
Timothy Tully
Filippo Cavalieri
Original Assignee
Cold Spring Harbor Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab filed Critical Cold Spring Harbor Lab
Application granted granted Critical
Publication of ATE526020T1 publication Critical patent/ATE526020T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Business, Economics & Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Theoretical Computer Science (AREA)
  • Educational Administration (AREA)
  • Educational Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Toys (AREA)
  • Rehabilitation Tools (AREA)
AT01963877T 2000-08-10 2001-08-10 Gesteigertes kognitives training ATE526020T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22422700P 2000-08-10 2000-08-10
PCT/US2001/025048 WO2002013867A2 (en) 2000-08-10 2001-08-10 Augmented cognitive training

Publications (1)

Publication Number Publication Date
ATE526020T1 true ATE526020T1 (de) 2011-10-15

Family

ID=22839775

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01963877T ATE526020T1 (de) 2000-08-10 2001-08-10 Gesteigertes kognitives training

Country Status (8)

Country Link
US (6) US7947731B2 (de)
EP (3) EP2316531A1 (de)
AT (1) ATE526020T1 (de)
AU (1) AU2001284792A1 (de)
DK (1) DK1355669T3 (de)
ES (1) ES2373540T3 (de)
PT (1) PT1355669E (de)
WO (1) WO2002013867A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
EP2316531A1 (de) 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Gesteigertes kognitives Training
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
EP1469852A4 (de) * 2002-01-04 2009-12-02 Ford Henry Health System Stickstoffdonoren zur behandlung von krankheit und verletzung
ATE463739T1 (de) 2002-08-19 2010-04-15 Helicon Therapeutics Inc Screening-verfahren für kognitive erweiterungsvorrichtungen
EP2177626B1 (de) * 2002-08-19 2013-12-18 Dart NeuroScience (Cayman) Ltd Abtastverfahren für kognitive Verstärker
US7725192B2 (en) * 2005-10-12 2010-05-25 The General Hospital Corporation Methods of increasing learning rate
ES2412481T3 (es) * 2006-05-19 2013-07-11 Dart Neuroscience Llc Inhibidores de la fosfodiesterasa 4 para la rehabilitación motora
GB2468811B (en) 2008-01-17 2012-12-19 Articulate Technologies Inc Methods and devices for intraoral tactile feedback
US9990859B2 (en) 2008-01-17 2018-06-05 Speech Buddies, Inc. Intraoral tactile biofeedback methods, devices and systems for speech and language training
KR20110049801A (ko) * 2008-07-18 2011-05-12 다트 뉴로사이언시즈, 엘엘씨 기억 물질의 평가를 위한 방법 및 시스템
CA2877146C (en) 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2014158916A1 (en) 2013-03-14 2014-10-02 Dart Neuroscience, Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
JP6282721B2 (ja) 2013-03-14 2018-02-21 ダート・ニューロサイエンス・（ケイマン）・リミテッド Ｐｄｅ４阻害剤としての置換ピリジン及びピラジン化合物
HUE057317T2 (hu) 2014-04-23 2022-04-28 Dart Neuroscience Llc Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
EP3134406A1 (de) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituierte 2,4,5,6-tetrahydropyrrolo [ 3,4-c ] pyrazol-und 4,5,6,7-tetrahydro-2 h-pyrazolo [ 4,3-c ] pyridinverbindungen als glyt1-inhibitoren
RU2017112054A (ru) * 2014-09-17 2018-10-17 Дарт Нюросайенс (Кайман) Лтд. Ингибиторы mao-b и реабилитация
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
EP3215500A1 (de) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituierte azetidinylverbindungen als glyt1-inhibitoren
WO2016179432A2 (en) 2015-05-05 2016-11-10 Dart Neuroscience, Llc Systems and methods for cognitive testing
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
WO2019014305A1 (en) 2017-07-12 2019-01-17 Dart Neuroscience, Llc SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS
DK3717488T3 (da) 2017-11-27 2021-12-13 Dart Neuroscience Llc Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
WO2019168866A1 (en) 2018-02-28 2019-09-06 Dart Neuroscience, Llc Substituted cyclohexyl compounds as nop inhibitors
GB201911024D0 (en) * 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
EP4252750A1 (de) 2022-03-31 2023-10-04 Leibniz-Institut für Neurobiologie Pharmazeutische konservierung der creb-aktivierung bei der behandlung von morbus alzheimer
CN120022498B (zh) * 2025-04-21 2025-07-15 吕梁学院 一种基于应用心理学记忆判断训练方法及训练装置

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686225A (en) * 1986-04-29 1987-08-11 American Home Products Corporation (Del.) Vinpocetine for pulmonary hemorrhage and edema
KR920702606A (ko) 1989-06-13 1992-10-06 스튜어트 알. 슈터 모노킨(Monokine)의 활성저해
JPH05503919A (ja) 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
JP2578001B2 (ja) 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
EP0651824A4 (de) 1992-04-10 1997-02-26 Fox Chase Cancer Center Transkriptionselement zur kontrolle der gesteigerten genexpression in myoblasten.
DE4310699A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
US6689557B1 (en) * 1994-10-07 2004-02-10 Cold Spring Harbor Laboratory Method of identifying a substance that affects long term memory and CREM/CREB/ATF-1 subfamily members
US5929223A (en) 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
ATE212227T1 (de) * 1995-02-15 2002-02-15 Takeda Chemical Industries Ltd Verwendung von kompocedinderivaten zur inhibierung der bildung oder sekretion von beta- amyloid-protein
ES2097703B1 (es) * 1995-04-12 1997-12-01 Decox S L Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.
US5882203A (en) * 1995-05-31 1999-03-16 Correa; Elsa I. Method of detecting depression
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
ATE256476T1 (de) 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
US6258794B1 (en) * 1999-12-14 2001-07-10 The Mclean Hospital Corporation Treatment of mental conditions including depression
US6270077B1 (en) * 1999-12-20 2001-08-07 Gene D. Cohen Non-competitive memory enhancement game
EP2316531A1 (de) 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Gesteigertes kognitives Training
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US20040053810A1 (en) 2002-08-16 2004-03-18 Tully Jo Anne Liquid laundry compositions comprising silicone additives
ATE463739T1 (de) 2002-08-19 2010-04-15 Helicon Therapeutics Inc Screening-verfahren für kognitive erweiterungsvorrichtungen
ES2412481T3 (es) * 2006-05-19 2013-07-11 Dart Neuroscience Llc Inhibidores de la fosfodiesterasa 4 para la rehabilitación motora
CA2877146C (en) * 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds

Also Published As

Publication number Publication date
US20130164721A1 (en) 2013-06-27
US20020076398A1 (en) 2002-06-20
EP2305353A1 (de) 2011-04-06
US8455538B2 (en) 2013-06-04
US20150141441A1 (en) 2015-05-21
PT1355669E (pt) 2012-01-02
AU2001284792A1 (en) 2002-02-25
ES2373540T3 (es) 2012-02-06
WO2002013867A3 (en) 2003-08-07
EP2316531A1 (de) 2011-05-04
US20130274704A1 (en) 2013-10-17
US20110224287A1 (en) 2011-09-15
DK1355669T3 (da) 2011-11-21
WO2002013867A2 (en) 2002-02-21
EP1355669A2 (de) 2003-10-29
US20110224146A1 (en) 2011-09-15
EP1355669B1 (de) 2011-09-28
US7947731B2 (en) 2011-05-24

Similar Documents

Publication Publication Date Title
ATE526020T1 (de) Gesteigertes kognitives training
DE602004017494D1 (de) Inhibitoren von p-38-kinase
DE60219961D1 (de) Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
WO2002098890A3 (en) MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
BRPI0410296A (pt) sistema e método para a determinação da eficácia de tratamento de distúrbios neurológicos utilizando o eletroencefalograma
PL373626A1 (en) Treatment for central nervous system disorders
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
CY1112817T1 (el) Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571
EE200300559A (et) Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks
WO2003015713A3 (en) Treatment of glial tumors with glutamate antagonists
WO2004091609A3 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
WO2001091745A3 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
GB0015228D0 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
WO2020080865A3 (ko) 치매 또는 우울증과 같은 뇌질환의 예방 및 치료를 위한 자기장 자극기를 장착한 마사지 장치 및 방법
WO2005010148A3 (en) Marks as modifiers of the pten pathway and methods of use
CY1116647T1 (el) Προσαυξημενη γνωσιακη εκπαιδευση
ATE373475T1 (de) Carbamate von 2-heterozyklischen 1,2-ethandiolen
WO2004058154A3 (en) Method of identifying therapeutic agents
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355669

Country of ref document: EP